MCF7/TAMR-7 Cell line
- Name Anne Lykkesfeldt
- Institute Danish Cancer Society
Tool name: MCF7/TAMR-7 Cell line
Tool type: Cell Lines
Tool sub-type: Continuous
Parental cell line: MCF7 S0.5
Cancer type: Breast cancer
Model: Tumour line
Description: The MCF7/TAMR-7 Cell line is a breast cancer cell line resistant to tamoxifen.Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-7 cell line is a good model cell to study the signalling pathways, which are the major drivers of tamoxifen-resistant growth.
Research area: Cancer; Drug development
Production details: The parental cell line for the MCF7/TAMR-7 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-7 has been established from a clone of cells that survived long term treatment with 1 ÄÂ??M tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 ÄÂ??M tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
Cellosaurus ID: 1D43
- For Research Use Only
- • Hole et al. 2015. Int J Oncol. 46(4):1481-90. PMID: 25625755.
- • Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.
- • New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
- • Pedersen et al. 2014. Int J Oncol. 45(5):2167-75. PMID: 25175082.
- • Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor a.
- • Lundqvist et al. 2014. Steroids. 85:30-5. PMID: 24747771.
- • Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
- • 1a,25-dihydroxyvitamin D3 inhibits cell growth and NFB signaling in tamoxifen-resistant breast cancer cells.
- • Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
- • Estrogen receptor a is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
- • Larsen et al. 2012. Int J Oncol. 41(5):1863-70. PMID: 22961366.
- • Carboplatin treatment of antiestrogen-resistant breast cancer cells.
- • Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.
- • Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
- • Berstein et al. 2003. Endocr Relat Cancer. 10(2):267-77. PMID: 12790788.
- • New approaches to the understanding of tamoxifen action and resistance.